These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 28326274)

  • 21. A five-gene signature may predict sunitinib sensitivity and serve as prognostic biomarkers for renal cell carcinoma.
    Chen YL; Ge GJ; Qi C; Wang H; Wang HL; Li LY; Li GH; Xia LQ
    J Cell Physiol; 2018 Oct; 233(10):6649-6660. PubMed ID: 29327492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic significance of VHL, HIF1A, HIF2A, VEGFA and p53 expression in patients with clear‑cell renal cell carcinoma treated with sunitinib as first‑line treatment.
    Wierzbicki PM; Klacz J; Kotulak-Chrzaszcz A; Wronska A; Stanislawowski M; Rybarczyk A; Ludziejewska A; Kmiec Z; Matuszewski M
    Int J Oncol; 2019 Aug; 55(2):371-390. PubMed ID: 31268155
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.
    Bai L; Yang JC; Ok JH; Mack PC; Kung HJ; Evans CP
    Int J Cancer; 2012 Jun; 130(11):2693-702. PubMed ID: 21792888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sunitinib resistance in renal cell carcinoma.
    Morais C
    J Kidney Cancer VHL; 2014; 1(1):1-11. PubMed ID: 28326244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elucidation and Regulation of Tyrosine Kinase Inhibitor Resistance in Renal Cell Carcinoma Cells from the Perspective of Glutamine Metabolism.
    Morozumi K; Kawasaki Y; Sato T; Maekawa M; Takasaki S; Shimada S; Sakai T; Yamashita S; Mano N; Ito A
    Metabolites; 2024 Mar; 14(3):. PubMed ID: 38535330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinoma.
    Sonpavde G; Willey CD; Sudarshan S
    Expert Opin Investig Drugs; 2014 Mar; 23(3):305-15. PubMed ID: 24387233
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PTEN Is Involved in Sunitinib and Sorafenib Resistance in Renal Cell Carcinoma.
    Sekino Y; Hagura T; Han X; Babasaki T; Goto K; Inoue S; Hayashi T; Teishima J; Shigeta M; Taniyama D; Kuraoka K; Sentani K; Yasui W; Matsubara A
    Anticancer Res; 2020 Apr; 40(4):1943-1951. PubMed ID: 32234883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents.
    Bellmunt J; Montagut C; Albiol S; Carles J; Maroto P; Orsola A
    BJU Int; 2007 Feb; 99(2):274-80. PubMed ID: 17092282
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolomic Analysis to Elucidate Mechanisms of Sunitinib Resistance in Renal Cell Carcinoma.
    Sato T; Kawasaki Y; Maekawa M; Takasaki S; Morozumi K; Sato M; Shimada S; Kawamorita N; Yamashita S; Mitsuzuka K; Mano N; Ito A
    Metabolites; 2020 Dec; 11(1):. PubMed ID: 33374949
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of IL13RA2 in Sunitinib Resistance in Clear Cell Renal Cell Carcinoma.
    Shibasaki N; Yamasaki T; Kanno T; Arakaki R; Sakamoto H; Utsunomiya N; Inoue T; Tsuruyama T; Nakamura E; Ogawa O; Kamba T
    PLoS One; 2015; 10(6):e0130980. PubMed ID: 26114873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib.
    Juengel E; Kim D; Makarević J; Reiter M; Tsaur I; Bartsch G; Haferkamp A; Blaheta RA
    J Cell Mol Med; 2015 Feb; 19(2):430-41. PubMed ID: 25444514
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rectovaginal fistula during treatment with axitinib in a patient with renal cell carcinoma: a case report and review of the literature.
    Nigro O; Pastore A; Tartaro T; Bolzacchini E; Tuzi A; Pinotti G
    Anticancer Drugs; 2019 Apr; 30(4):425-427. PubMed ID: 30640790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Lysosomal Sequestration of Tyrosine Kinase Inhibitors and Drug Resistance.
    Ruzickova E; Skoupa N; Dolezel P; Smith DA; Mlejnek P
    Biomolecules; 2019 Oct; 9(11):. PubMed ID: 31683643
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
    Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K
    Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oncogenic effects of RAB27B through exosome independent function in renal cell carcinoma including sunitinib-resistant.
    Tsuruda M; Yoshino H; Okamura S; Kuroshima K; Osako Y; Sakaguchi T; Sugita S; Tatarano S; Nakagawa M; Enokida H
    PLoS One; 2020; 15(5):e0232545. PubMed ID: 32379831
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutations of the von Hippel-Lindau gene confer increased susceptibility to natural killer cells of clear-cell renal cell carcinoma.
    Perier A; Fregni G; Wittnebel S; Gad S; Allard M; Gervois N; Escudier B; Azzarone B; Caignard A
    Oncogene; 2011 Jun; 30(23):2622-32. PubMed ID: 21258414
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trichostatin A modulates cellular metabolism in renal cell carcinoma to enhance sunitinib sensitivity.
    Sato H; Uzu M; Kashiba T; Fujiwara T; Hatakeyama H; Ueno K; Hisaka A
    Eur J Pharmacol; 2019 Mar; 847():143-157. PubMed ID: 30689992
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Photochemically-Induced Release of Lysosomal Sequestered Sunitinib: Obstacles for Therapeutic Efficacy.
    Wong JJW; Berstad MB; Fremstedal ASV; Berg K; Patzke S; Sørensen V; Peng Q; Selbo PK; Weyergang A
    Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32053965
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma.
    Motzer RJ; Escudier B; Gannon A; Figlin RA
    Oncologist; 2017 Jan; 22(1):41-52. PubMed ID: 27807302
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resistance to Targeted Therapies in Renal Cancer: The Importance of Changing the Mechanism of Action.
    Duran I; Lambea J; Maroto P; González-Larriba JL; Flores L; Granados-Principal S; Graupera M; Sáez B; Vivancos A; Casanovas O
    Target Oncol; 2017 Feb; 12(1):19-35. PubMed ID: 27844272
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.